BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia

It isn’t often that a single company has an advisory committee meeting for one product and an FDA decision for another in the same week. Even more unusual is when the two drugs are of the same therapeutic class.

That’s what’s happening this week for Bristol Myers Squibb, though, as the regulator approved the company’s CAR-T treatment, Breyanzi, late on Thursday for chronic lymphocytic leukemia and small lymphocytic leukemia ahead of Friday’s meeting about Abecma, another CAR-T therapy, which will be discussed alongside Johnson & Johnson’s Carvykti for use as earlier lines of treatment in multiple myeloma.